True North Clinical Research

Providing Hope to Present and Future Generations

True North Clinical Research is committed to the health and wellness of patients living in Nova Scotia.

Why Clinical Research?

Clinical trials are an essential part of the research and development of all pharmaceutical drugs. All medication, whether sold through prescription or over-the-counter, must undergo comprehensive testing to ensure they treat the condition or conditions they were designed and created to treat without significant risk to those taking them.

Each and every trial we conduct is done so under strict guidelines, which are monitored by Health Canada. Health Canada approves the use of investigational medications within clinical trials, before these medications are approved for use by the general public. A Principal Investigator – a medical doctor trained to conduct research trials in a safe, ethical and controlled manner – oversees each of our research trials.

In order to qualify for a trial, participants are screened and must meet a strict criteria. Those participants who qualify to enroll in a trial will be required to attend a variety of appointments and their progress will be carefully tracked. During these visits, participants will work with our clinical staff and investigators. These visits could potentially include questionnaires, blood collection, physical exams, and diagnostic tests.

It should be noted that each participant is fully educated as to what to expect prior to undergoing any trial-related assessments that may be required.

Importance and Benefits of Participation

 

  • Contribution to the future development of medications worldwide
  • Access to potential treatment options that is currently not available to the general public
  • Constant monitoring and care provided by highly trained professionals
  • On-going support provided by clinical research staff
True North Clinical Memory and Alzheimer Conditions
How do I learn more?
If you are interested in learning more about clinical trials, or wish to inquire about out current or future trials, click here to contact us and one of our highly trained staff will be in touch to provide more information.

Recruiting Clinical Trials

Currently Recruiting New Participants
Alzheimer’s Disease Prevention

Generation Program – In association with Norvartis Pharmaceuticals, True North Clinical Research is researching two different investigational medications vs placebo in those who are genetically at a higher risk of developing Alzheimer’s disease but who are not currently experiencing any memory impairment. These clinical trials involve preliminary genetic testing, looking specifically at the ApoE gene. Those who carry an ApoE4 allele, which is associated with a higher risk of developing Alzheimer’s disease, may then be eligible to be screened for one of the two clinical trials focused on prevention. The Generation Program is looking at how both a BACE inhibitors and a monoclonal antibody affect cognition, clinical status, and underlying pathology of participants at risk for the onset of clinical symptoms of Alzheimer’s disease.

Alzheimer’s Disease – MissionAD

Together with Eisai Co., Ltd., True North Clinical Research is researching an investigational medication vs placebo in those with early Alzheimer’s disease. This trial is evaluating the relationship between daily oral administration of Elenbecestat (a BACE inhibitor) and the cognitive and functional abilities of trial participants. Elenbecestat is designed to prevent the accumulation of beta-amyloid plaque in the brain and the theory is that by doing so, they will slow down the progression of Alzheimer’s disease.

Alzheimer’s Disease – BI 1346.23

True North Clinical Research is involved in a clinical trial with Boehringer Ingelheim, researching an investigational medication vs placebo in those with mild-moderate Alzheimer’s disease. The investigational medication being studied is designed to increase memory abilities in those with cognitive impairment. Participants are allowed to already be taking an acetylcholinesterase inhibitor such as Aricept and still participate in the trial. This trial is evaluating the relationship between the investigational medication and the cognitive abilities of participants over a 12 week period.

Ongoing Clinical Trials

Recruitment Closed
Alzheimer’s Disease

CREAD2 – Along with Hoffman-La Roche, True North Clinical Research is involved in a clinical trial researching crenezumab vs placebo in patients with prodromal-mild Alzheimer’s disease. This trial is evaluating the relationship between monthly intravenous infusions of crenezumab (a monoclonal antibody) and the cognitive and functional abilities of trial participants. Crenezumab is designed to remove beta-amyloid plaque from the brain and the theory is that by doing so, they will slow down the progression of Alzheimer’s disease.

Emerge

True North Clinical Research is involved in a clinical trial with Biogen, researching aducanumab vs placebo in patients with early Alzheimer’s disease. This trial is evaluating the relationship between monthly intravenous infusions of aducanumab (a monoclonal antibody) and the cognitive and functional abilities of trial participants. Aducanumab is designed to remove beta-amyloid plaque from the brain and the theory is that by doing so, they will slow down the progression of Alzheimer’s disease.

Daybreak

In conjunction with Eli Lilly and Company, True North Clinical Research is involved in a clinical trial researching lanabecestat vs placebo in patients with mild Alzheimer’s disease. This trial is evaluating the relationship between daily oral administration of lanabecestat (a BACE inhibitor) and the cognitive and functional abilities of trial participants. Lanabecestat is designed to prevent the accumulation of beta-amyloid plaque in the brain and the theory is that by doing so, they will slow down the progression of Alzheimer’s disease.

Amaranth

Working alongside with Eli Lilly and Company, True North Clinical Research is involved in a clinical trial researching lanabecestat vs placebo in patients with early Alzheimer’s disease. This trial is evaluating the relationship between daily oral administration of lanabecestat (a BACE inhibitor) and the cognitive and functional abilities of trial participants. Lanabecestat is designed to prevent the accumulation of beta-amyloid plaque in the brain and the theory is that by doing so, they will slow down the progression of Alzheimer’s disease.

Scarlet Road

True North Clinical Research is involved in a clinical trial with Hoffman-La Roche, researching gantenerumab in patients with prodromal Alzheimer’s disease. This trial is evaluating the relationship between monthly subcutaneous infusions of gantenerumab (a monoclonal antibody) and the cognitive and functional abilities of trial participants. Gantenerumab is designed to remove beta-amyloid plaque from the brain and the theory is that by doing so, they will slow down the progression of Alzheimer’s disease.

Marguerite Road

With Hoffman-La Roche, True North Clinical Research is involved in a clinical trial researching gantenerumab in patients with mild Alzheimer’s disease. This trial is evaluating the relationship between monthly subcutaneous infusions of gantenerumab (a monoclonal antibody) and the cognitive and functional abilities of trial participants. Gantenerumab is designed to remove beta-amyloid plaque from the brain and the theory is that by doing so, they will slow down the progression of Alzheimer’s disease.

Type 2 Diabetes Mellitus

Themis – True North Clinical Research is involved in a clinical trial evaluating the effects of an already-marketed medication Ticagrelor, compared to placebo, in the prevention of major cardiovascular events in patients with Type 2 Diabetes Mellitus who are at high risk of cardiovascular events but have not previously experienced a stroke or a heart attack.

Completed Clinical Trials

True North Clinical Research has proudly participated in many trials that have the potential to impact the lives of hundreds of thousands of people around the globe. Below is a list of some of our completed trails.